Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction

Diabetes

Volumn 62, Issue 2, 2013, Pages 498-509

  Hua, Yinan ^a   Zhang, Yingmei ^a   Dolence, Julia ^a   Shi, Guo Ping ^b   Ren, Jun ^a   Nair, Sreejayan ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; CYTOCHROME C; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTRACTILE DYSFUNCTION; CONTROLLED STUDY; GLUCOSE INTOLERANCE; HEART DISEASE; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; LIPID DIET; LYSOSOME; MALE; MITOCHONDRION; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WILD TYPE;

ANIMALS; APOPTOSIS; CALCIUM; CARDIOMEGALY; CATHEPSIN K; CELL LINE; CYTOCHROMES C; CYTOPLASM; DIET, HIGH-FAT; ENZYME INHIBITORS; GENE SILENCING; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; INSULIN; LYSOSOMES; MALE; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; OBESITY; PALMITIC ACID; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; VENTRICULAR REMODELING;

EID: 84873025790     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0350     Document Type: Article

References (41)

1. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 2006;29:1697-1699
2. Poirier P, Giles TD, Bray GA, et al.; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918
3. Thomas F, Bean K, Pannier B, Oppert JM, Guize L, Benetos A. Cardiovascular mortality in overweight subjects: the key role of associated risk factors. Hypertension 2005;46:654-659
4. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991; 266:231-236
5. Alexander JK. Obesity and the heart. Heart Dis Stroke 1993;2:317-321
6. Morricone L, Malavazos AE, Coman C, Donati C, Hassan T, Caviezel F. Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res 2002;10:489-498
7. Wisse BE, Kim F, Schwartz MW. Physiology. An integrative view of obesity. Science 2007;318:928-929
8. Young ME, Guthrie PH, Razeghi P, et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002;51:2587-2595
9. Dong F, Zhang X, Yang X, et al. Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice. J Endocrinol 2006;188:25-36
10. Fedak PW, Verma S, Weisel RD, Li RK. Cardiac remodeling and failure From molecules to man (Part II). Cardiovasc Pathol 2005;14:49-60
11. Ballal K, Wilson CR, Harmancey R, Taegtmeyer H. Obesogenic high fat western diet induces oxidative stress and apoptosis in rat heart. Mol Cell Biochem 2010;344:221-230
12. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010;120:3421-3431
13. Qin Y, Shi GP. Cysteinyl cathepsins and mast cell proteases in the patho-genesis and therapeutics of cardiovascular diseases. Pharmacol Ther 2011; 131:338-350
14. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012;125:1551-1562
15. Taleb S, Lacasa D, Bastard JP, et al. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J 2005;19:1540-1542
16. Liu J, Ma L, Yang J, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006;186:411-419
17. Chwieralski CE, Welte T, Bühling F. Cathepsin-regulated apoptosis. Apoptosis 2006;11:143-149
18. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998;102:576-583
19. Cheng XW, Kuzuya M, Sasaki T, et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004;164:243-251
20. Helske S, Syväranta S, Lindstedt KA, et al. Increased expression of elas-tolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol 2006;26:1791-1798
21. Cheng XW, Obata K, Kuzuya M, et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006;48:979-987
22. Ge J, Zhao G, Chen R, et al. Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. Eur J Heart Fail 2006;8:284-289
23. Tang Q, Cai J, Shen D, et al. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med (Berl) 2009;87:249-260
24. Yang M, Sun J, Zhang T, et al. Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arte-rioscler Thromb Vasc Biol 2008;28:2202-2208
25. Li CY, Jepsen KJ, Majeska RJ, et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 2006;21:865-875
26. Ceylan-Isik AF, Sreejayan N, Ren J. Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunction. J Mol Cell Cardiol 2011;50:107-116
27. Doser TA, Turdi S, Thomas DP, Epstein PN, Li SY, Ren J. Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation 2009;119:1941-1949
28. Chavez JA, Knotts TA, Wang LP, et al. A role for ceramide, but not diac-ylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003;278:10297-10303
29. Dong F, Li Q, Sreejayan N, Nunn JM, Ren J. Metallothionein prevents high-fat diet induced cardiac contractile dysfunction: role of peroxisome pro-liferator activated receptor gamma coactivator 1alpha and mitochondrial biogenesis. Diabetes 2007;56:2201-2212
30. Petermann I, Mayer C, Stypmann J, et al. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J 2006;20:1266-1268
31. Spira D, Stypmann J, Tobin DJ, et al. Cell type-specific functions of the lysosomal protease cathepsin L in the heart. J Biol Chem 2007;282:37045-37052
32. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784-1789
33. Nakayama H, Otsu K, Yamaguchi O, et al. Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 2003;17:61-63
34. Zhai J, Schmidt AG, Hoit BD, Kimura Y, MacLennan DH, Kranias EG. Cardiac-specific overexpression of a superinhibitory pentameric phos-pholamban mutant enhances inhibition of cardiac function in vivo. J Biol Chem 2000;275:10538-10544
35. Matsusaka H, Ide T, Matsushima S, et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006;47:711-717
36. Chaanine AH, Hajjar RJ. AKT signalling in the failing heart. Eur J Heart Fail 2011;13:825-829
37. Shiojima I, Yefremashvili M, Luo Z, et al. Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem 2002;277:37670-37677
38. Kemi OJ, Ceci M, Wisloff U, et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol 2008;214:316-321
39. González A, Ravassa S, López B, Loperena I, Querejeta R, Díez J. Apoptosis in hypertensive heart disease: a clinical approach. Curr Opin Cardiol 2006; 21:288-294
40. Fortuño MA, González A, Ravassa S, López B, Díez J. Clinical implications of apoptosis in hypertensive heart disease. Am J Physiol Heart Circ Physiol 2003;284:H1495-H1506
41. Yamashima T. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates. Prog Neurobiol 2000; 62:273-295